The market for CAR-T Cell Therapy Market is expected to reach US$ XX Bn in 2026.
The CAR-T cell therapy market was valued at US$ 72.0 Mn in 2017 and is projected to exhibit a double-digit compound annual growth rate (CAGR) of 51.1% during the forecast period from 2018 to 2026. Scientists have encountered the biggest challenge in treating cancer: the cancer cells with the disease progression usually become invisible to the body’s defense mechanism. Immunotherapy is the future in treating cancer, where the immune cells are genetically engineered to recognize the biomarkers of cancerous cells, target them, and kill them. CAR-T cell therapy does not kill normal healthy cells and has proven effective in relapsed cancer treatment. The CAR-T cell therapy market is driven by factors such as cancer's rising prevalence, growing immune-oncology research, and massive funding from government health institutions and pharma giants in CAR-T cell therapy development. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection, and chemotherapy to kill the leukemia cells in the bone marrow. However, advances in cell therapy and gene therapy have rendered the development of oncology treatment by the body’s immune system. The FDA-approved CAR-T cell therapy is Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently, CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. There are more than 2,000 candidates in the clinical trials for different cancer indications.
CD 19 antigens are currently being studied extensively to prove their efficacy in the treatment of acute lymphoblastic leukemia. The rising prevalence of acute lymphoblastic leukemia in children and adults has buttressed the dominance of CD 19 antigens for cancer therapy. Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) are the two approved CD19 therapies and the only CAR-T cell therapies currently approved in the market. In addition, CD 22 and CD 30 antigens are being studied diligently in the preclinical trials with promising results for the treatment of B cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma, respectively.
The non-Hodgkin’s lymphoma segment dominated the market in 2017 owing to a surge in the number of NHL cases coupled with the higher adoption of YESCARTA (axicabtagene ciloleucel) Kymriah (tisagenlecleucel, formerly CTL019) around the world. CAR T cell therapy products are currently only indicated in non-Hodgkin’s lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia. However, clinical trials of some CAR T cell therapy drugs being studied (under study) for the treatment of multiple myeloma, acute myeloid leukemia, melanoma, glioblastomas, myelodysplastic syndromes (MDS), and cancer of pancreatitis, prostate, bladder, esophagus, stomach, liver, lung, kidney, & cervix. Thus, proliferating application of CAR-T in various indications would further boost the market during the forecast period.
In 2017, North America demonstrated supremacy in the global CAR-T cell therapy market owing to the exclusive availability of the two approved products, Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.). Developed healthcare infrastructure, high accessibility to advanced therapies, rise in healthcare expenditure, incessant investment in R&D activities, and presence of established market leaders further catalyze the overall market growth in this region. With Medicare constantly working on structuring suitable reimbursement policies for dynamically priced CAR-T cell therapies, the demand for it is projected to increase during the forecast period. In the Asia Pacific, the market entry of Kymriah is expected by the end of 2018 in Japan. The extensive pipeline portfolio for CAR-T cell therapy in China and the continuous growing cancer prevalence in Asia Pacific regions predominantly contribute to the maximum growth.
2016 – Historical Year
2017 – Base Year
2018-2026 – Forecast Period
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment calculated for the forecast period from 2018 to 2026.
The CAR-T cell therapy market report furnishes quantitative analysis and its latest market trends. The market is segmented based on antigen type, indication, and geography.
Market is studied in order to understand the current and future market trends in the CAR-T cell therapy market. The market is estimated by providing the compounded annual growth rate (CAGR) and data forecast from 2018 to 2026. In addition, strategic acquisition, merger, and collaboration among the key players for developing innovative product pipelines are mentioned in the business strategy section. The key players currently engaged in the CAR-T cell therapy market are Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Juno Therapeutics, Cellectis, Eureka Therapeutics, Kite Pharma, Sorrento Therapeutics and Novartis AG, Gilead Sciences among others.
The market for CAR-T Cell Therapy Market is expected to reach US$ XX Bn in 2026.
The CAR-T Cell Therapy Market is expected to see significant CAGR growth over the coming years, at 51.1%.
The report is forecasted from 2017-2026.
The base year of this report is 2017.
Bellicum Pharmaceuticals, Inc., Celgene Corporation, Cellectis, Eureka Therapeutics, Inc., Immune Therapeutics, Inc. are some of the major players in the global market.